Preview

Кардиология

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Риск развития коронарных осложнений при фибрилляции предсердий

https://doi.org/10.18087/cardio.2020.1.n828

Полный текст:

Аннотация

Установлено, что в популяции пациентов с фибрилляцией предсердий частота развития сердечно-сосудистых осложнений, связанных с ишемической болезнью сердца, остается высокой. В настоящем обзоре подробно рассматриваются эпидемиологические данные, подтверждающие данную взаимосвязь, и патофизиологические механизмы, позволяющие ее объяснить. Обсуждаются способы прогнозирования и профилактики коронарных осложнений при мерцательной аритмии, включая модификацию общих факторов риска, антитромботическую терапию, а также вопросы выбора прямого перорального антикоагулянта с наиболее благоприятным влиянием на кардиальные ишемические исходы.

Об авторах

Ж. Д. Кобалава
ФГАОУВО «Российский университет дружбы народов» (РУДН)
Россия

Москва



П. В. Лазарев
ФГАОУВО «Российский университет дружбы народов» (РУДН)
Россия

Лазарев Павел Валерьевич

Москва




Список литературы

1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893–962. DOI: 10.1093/eurheartj/ehw210

2. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal. 2018;39(16):1330– 93. DOI: 10.1093/eurheartj/ehy136

3. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125–51. DOI: 10.1161/CIR.0000000000000665

4. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2009;361(12):1139–51. DOI: 10.1056/NEJMoa0905561

5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011;365(10):883–91. DOI: 10.1056/NEJMoa1009638

6. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2011;365(11):981–92. DOI: 10.1056/NEJMoa1107039

7. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine. 2013;369(22):2093–104. DOI: 10.1056/NEJMoa1310907

8. Gómez-Outes A, Lagunar-Ruíz J, Terleira-Fernández A-I, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Causes of Death in Anticoagulated Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 2016;68(23):2508–21. DOI: 10.1016/j.jacc.2016.09.944

9. Börschel CS, Schnabel RB. The imminent epidemic of atrial fibrillation and its concomitant diseases – Myocardial infarction and heart failure A cause for concern. International Journal of Cardiology. 2019;287:162–73. DOI: 10.1016/j.ijcard.2018.11.123

10. Montalescot G, Sechtem W, Achenbach S, Andreotti F, Arden C, Budaj A et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal. 2013;34(38):2949–3003. DOI: 10.1093/eurheartj/eht296

11. Andrade J, Khairy P, Dobrev D, Nattel S. The Clinical Profile and Pathophysiology of Atrial Fibrillation: Relationships Among Clinical Features, Epidemiology, and Mechanisms. Circulation Research. 2014;114(9):1453–68. DOI: 10.1161/CIRCRESAHA.114.303211

12. Lip GYH, Laroche C, Dan G-A, Santini M, Kalarus Z, Rasmussen LH et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORPAF) Pilot General Registry. EP Europace. 2014;16(3):308–19. DOI: 10.1093/europace/eut373

13. Kralev S, Schneider K, Lang S, Süselbeck T, Borggrefe M. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PloS One. 2011;6(9):e24964. DOI: 10.1371/journal.pone.0024964

14. Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey J-Y, Schilling RJ et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events – European Registry in Atrial Fibrillation (PREFER in AF). EP Europace. 2014;16(1):6–14. DOI: 10.1093/europace/eut263

15. Michniewicz E, Mlodawska E, Lopatowska P, Tomaszuk-Kazberuk A, Malyszko J. Patients with atrial fibrillation and coronary artery disease Double trouble. Advances in Medical Sciences. 2017;63(1):30– 5. DOI: 10.1016/j.advms.2017.06.005

16. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199–267. DOI: 10.1161/CIR.0000000000000041

17. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271(11):840–4. PMID: 8114238

18. Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA et al. Atrial fibrillation and the risk of myocardial infarction. JAMA internal medicine. 2014;174(1):107–14. DOI: 10.1001/jamainternmed.2013.11912

19. He W, Chu Y. Atrial fibrillation as a prognostic indicator of myocardial infarction and cardiovascular death: a systematic review and metaanalysis. Scientific Reports. 2017;7(1):3360. DOI: 10.1038/s41598-017-03653-5

20. Emdin CA, Wong CX, Hsiao AJ, Altman DG, Peters SA, Woodward M et al. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies. BMJ. 2016;532:h7013. DOI: 10.1136/bmj.h7013

21. Soliman EZ, Lopez F, O’Neal WT, Chen LY, Bengtson L, Zhang Z-M et al. Atrial Fibrillation and Risk of ST-Segment-Elevation Versus Non-ST-Segment-Elevation Myocardial Infarction: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2015;131(21):1843–50. DOI: 10.1161/CIRCULATIONAHA.114.014145

22. Chao T-F, Huang Y-C, Liu C-J, Chen S-J, Wang K-L, Lin Y-J et al. Acute myocardial infarction in patients with atrial fibrillation with a CHA2DS2-VASc score of 0 or 1: A nationwide cohort study. Heart Rhythm. 2014;11(11):1941–7. DOI: 10.1016/j.hrthm.2014.08.003

23. Reinier K, Marijon E, Uy-Evanado A, Teodorescu C, Narayanan K, Chugh H et al. The Association Between Atrial Fibrillation and Sudden Cardiac Death. JACC: Heart Failure. 2014;2(3):221–7. DOI: 10.1016/j.jchf.2013.12.006

24. Bayturan O, Puri R, Tuzcu EM, Shao M, Wolski K, Schoenhagen P et al. Atrial fibrillation, progression of coronary atherosclerosis and myocardial infarction. European Journal of Preventive Cardiology. 2017;24(4):373–81. DOI: 10.1177/2047487316679265

25. Crenshaw BS, Ward SR, Granger CB, Stebbins AL, Topol EJ, Califf RM. Atrial Fibrillation in the Setting of Acute Myocardial Infarction: The GUSTO-I Experience fn1fn1This study was funded by grants from Genentech, South San Francisco, California; Bayer Corporation, New York, New York; CIBA-Corning, Medfield, Massachusetts; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France. Journal of the American College of Cardiology. 1997;30(2):406–13. DOI: 10.1016/S0735-1097(97)00194-0

26. Jons C, Jacobsen UG, Joergensen RM, Olsen NT, Dixen U, Johannessen A et al. The incidence and prognostic significance of new-onset atrial fibrillation in patients with acute myocardial infarction and left ventricular systolic dysfunction: A CARISMA substudy. Heart Rhythm. 2011;8(3):342–8. DOI: 10.1016/j.hrthm.2010.09.090

27. Jabre P, Roger VL, Murad MH, Chamberlain AM, Prokop L, Adnet F et al. Mortality Associated With Atrial Fibrillation in Patients With Myocardial Infarction: A Systematic Review and Meta-Analysis. Circulation. 2011;123(15):1587–93. DOI: 10.1161/CIRCULATIONAHA.110.986661

28. Kundu A, O’Day K, Shaikh AY, Lessard DM, Saczynski JS, Yarzebski J et al. Relation of Atrial Fibrillation in Acute Myocardial Infarction to In-Hospital Complications and Early Hospital Readmission. The American Journal of Cardiology. 2016;117(8):1213–8. DOI: 10.1016/j.amjcard.2016.01.012

29. Chaikriangkrai K, Valderrabano M, Bala SK, Alchalabi S, Graviss EA, Nabi F et al. Prevalence and Implications of Subclinical Coronary Artery Disease in Patients With Atrial Fibrillation. The American Journal of Cardiology. 2015;116(8):1219–23. DOI: 10.1016/j.amjcard.2015.07.041

30. O’Neal WT, Efird JT, Qureshi WT, Yeboah J, Alonso A, Heckbert SR et al. Coronary Artery Calcium Progression and Atrial Fibrillation: The Multi-Ethnic Study of Atherosclerosis. Circulation: Cardiovascular Imaging. 2015;8(12):e003786. DOI: 10.1161/CIRCIMAGING.115.003786

31. Lokshyn S, Mewis C, Kuhlkamp V. Atrial fibrillation in coronary artery disease. International Journal of Cardiology. 2000;72(2):133–6. PMID: 10646954

32. Motloch LJ, Reda S, Larbig R, Wolff A, Motloch KA, Wernly B et al. Characteristics of coronary artery disease among patients with atrial fibrillation compared to patients with sinus rhythm. Hellenic Journal of Cardiology. 2017;58(3):204–12. DOI: 10.1016/j.hjc.2017.03.001

33. Guo Y, Lip GYH, Apostolakis S. Inflammation in atrial fibrillation. Journal of the American College of Cardiology. 2012;60(22):2263–70. DOI: 10.1016/j.jacc.2012.04.063

34. da Silva RMFL. Influence of Inflammation and Atherosclerosis in Atrial Fibrillation. Current Atherosclerosis Reports. 2017;19(1):2. DOI: 10.1007/s11883-017-0639-0

35. Hu Y-F, Chen Y-J, Lin Y-J, Chen S-A. Inflammation and the pathogenesis of atrial fibrillation. Nature Reviews Cardiology. 2015;12(4):230–43. DOI: 10.1038/nrcardio.2015.2

36. Hijazi Z, Aulin J, Andersson U, Alexander JH, Gersh B, Granger CB et al. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart. 2016;102(7):508–17. DOI: 10.1136/heartjnl-2015-308887

37. Lim HS, Willoughby SR, Schultz C, Gan C, Alasady M, Lau DH et al. Effect of atrial fibrillation on atrial thrombogenesis in humans: impact of rate and rhythm. Journal of the American College of Cardiology. 2013;61(8):852–60. DOI: 10.1016/j.jacc.2012.11.046

38. Shibata T, Kawakami S, Noguchi T, Tanaka T, Asaumi Y, Kanaya T et al. Prevalence, Clinical Features, and Prognosis of Acute Myocardial Infarction Attributable to Coronary Artery Embolism. Circulation. 2015;132(4):241–50. DOI: 10.1161/CIRCULATIONAHA.114.015134

39. Luo C, Wang L, Feng C, Zhang W, Huang Z, Hao Y et al. Predictive value of coronary blood flow for future cardiovascular events in patients with atrial fibrillation. International Journal of Cardiology. 2014;177(2):545–7. DOI: 10.1016/j.ijcard.2014.08.102

40. Wong CX, Lim HS, Schultz CD, Sanders P, Worthley MI, Willoughby SR. Assessment of endothelial function in atrial fibrillation: utility of peripheral arterial tonometry: Endothelial function in atrial fibrillation. Clinical and Experimental Pharmacology and Physiology. 2012;39(2):141–4. DOI: 10.1111/j.1440-1681.2011.05647.x

41. Goette A, Bukowska A, Dobrev D, Pfeiffenberger J, Morawietz H, Strugala D et al. Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles. European Heart Journal. 2009;30(11):1411–20. DOI: 10.1093/eurheartj/ehp046

42. Sandoval Y, Smith SW, Thordsen SE, Apple FS. Supply/demand type 2 myocardial infarction: should we be paying more attention? Journal of the American College of Cardiology. 2014;63(20):2079–87. DOI: 10.1016/j.jacc.2014.02.541

43. Heeringa J, van der Kuip DAM, Hofman A, Kors JA, van Herpen G, Stricker BHCh et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. European Heart Journal. 2006;27(8):949–53. DOI: 10.1093/eurheartj/ehi825

44. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP et al. Heart Disease and Stroke Statistics–2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56–528. DOI: 10.1161/CIR.0000000000000659

45. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet (London, England). 2015;386(9989):154–62. DOI: 10.1016/S0140-6736(14)61774-8

46. Dun W, Boyden PA. Aged atria: electrical remodeling conducive to atrial fibrillation. Journal of Interventional Cardiac Electrophysiology. 2009;25(1):9–18. DOI: 10.1007/s10840-008-9358-3

47. Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Otsuka T et al. Impact of blood pressure control on thromboembolism and major hemorrhage in patients with nonvalvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry. Journal of the American Heart Association. 2016;5(9):e004075. DOI: 10.1161/JAHA.116.004075

48. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet. 2004;364(9438):937–52. DOI: 10.1016/S0140-6736(04)17018-9

49. Magnussen C, Niiranen TJ, Ojeda FM, Gianfagna F, Blankenberg S, Njølstad I et al. Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). Circulation. 2017;136(17):1588–97. DOI: 10.1161/CIRCULATIONAHA.117.028981

50. Vemulapalli S, Inohara T, Kim S, Thomas L, Piccini JP, Patel MR et al. Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry). The American Journal of Cardiology. 2019;123(10):1628–36. DOI: 10.1016/j.amjcard.2019.02.010

51. Toh N, Kanzaki H, Nakatani S, Ohara T, Kim J, Kusano KF et al. Left Atrial Volume Combined With Atrial Pump Function Identifies Hypertensive Patients With a History of Paroxysmal Atrial Fibrillation. Hypertension. 2010;55(5):1150–6. DOI: 10.1161/HYPERTENSIONAHA.109.137760

52. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace. 2011;13(3):308–28. DOI: 10.1093/europace/eur002

53. Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in Obesity Among Adults in the United States, 2005 to 2014. JAMA. 2016;315(21):2284–91. DOI: 10.1001/jama.2016.6458

54. Huxley RR, Misialek JR, Agarwal SK, Loehr LR, Soliman EZ, Chen LY et al. Physical Activity, Obesity, Weight Change, and Risk of Atrial Fibrillation: The Atherosclerosis Risk in Communities Study. Circulation: Arrhythmia and Electrophysiology. 2014;7(4):620–5. DOI: 10.1161/CIRCEP.113.001244

55. Wong CX, Sullivan T, Sun MT, Mahajan R, Pathak RK, Middeldorp M et al. Obesity and the Risk of Incident, Post-Operative, and Post-Ablation Atrial Fibrillation. JACC: Clinical Electrophysiology. 2015;1(3):139–52. DOI: 10.1016/j.jacep.2015.04.004

56. Tedrow UB, Conen D, Ridker PM, Cook NR, Koplan BA, Manson JE et al. The Longand Short-Term Impact of Elevated Body Mass Index on the Risk of New Atrial Fibrillation. Journal of the American College of Cardiology. 2010;55(21):2319–27. DOI: 10.1016/j.jacc.2010.02.029

57. Abed HS, Samuel CS, Lau DH, Kelly DJ, Royce SG, Alasady M et al. Obesity results in progressive atrial structural and electrical remodeling: Implications for atrial fibrillation. Heart Rhythm. 2013;10(1):90– 100. DOI: 10.1016/j.hrthm.2012.08.043

58. Alpert MA, Omran J, Bostick BP. Effects of Obesity on Cardiovascular Hemodynamics, Cardiac Morphology, and Ventricular Function. Current Obesity Reports. 2016;5(4):424–34. DOI: 10.1007/s13679-016-0235-6

59. Wong CX, Abed HS, Molaee P, Nelson AJ, Brooks AG, Sharma G et al. Pericardial Fat Is Associated With Atrial Fibrillation Severity and Ablation Outcome. Journal of the American College of Cardiology. 2011;57(17):1745–51. DOI: 10.1016/j.jacc.2010.11.045

60. Munger TM, Dong Y-X, Masaki M, Oh JK, Mankad SV, Borlaug BA et al. Electrophysiological and Hemodynamic Characteristics Associated With Obesity in Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 2012;60(9):851–60. DOI: 10.1016/j.jacc.2012.03.042

61. Huxley RR, Alonso A, Lopez FL, Filion KB, Agarwal SK, Loehr LR et al. Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study. Heart. 2012;98(2):133–8. DOI: 10.1136/heartjnl-2011-300503

62. Neilan TG, Farhad H, Dodson JA, Shah RV, Abbasi SA, Bakker JP et al. Effect of Sleep Apnea and Continuous Positive Airway Pressure on Cardiac Structure and Recurrence of Atrial Fibrillation. Journal of the American Heart Association. 2013;2(6):e000421. DOI: 10.1161/JAHA.113.000421

63. Gottlieb DJ, Yenokyan G, Newman AB, O’Connor GT, Punjabi NM, Quan SF et al. Prospective Study of Obstructive Sleep Apnea and Incident Coronary Heart Disease and Heart Failure: The Sleep Heart Health Study. Circulation. 2010;122(4):352–60. DOI: 10.1161/CIRCULATIONAHA.109.901801

64. Zhu W, Yuan P, Shen Y, Wan R, Hong K. Association of smoking with the risk of incident atrial fibrillation: A meta-analysis of prospective studies. International Journal of Cardiology. 2016;218:259–66. DOI: 10.1016/j.ijcard.2016.05.013

65. Mourtzinis G, Kahan T, Bengtsson Boström K, Schiöler L, Cedstrand Wallin L, Hjerpe P et al. Relation Between Lipid Profile and New-Onset Atrial Fibrillation in Patients With Systemic Hypertension (From the Swedish Primary Care Cardiovascular Database [SPCCD]). The American Journal of Cardiology. 2018;122(1):102–7. DOI: 10.1016/j.amjcard.2018.03.024

66. van Diepen S, Hellkamp AS, Patel MR, Becker RC, Breithardt G, Hacke W et al. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circulation. Heart Failure. 2013;6(4):740–7. DOI: 10.1161/CIRCHEARTFAILURE.113.000212

67. Bansilal S, Bloomgarden Z, Halperin JL, Hellkamp AS, Lokhnygina Y, Patel MR et al. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). American Heart Journal. 2015;170(4):675-682. e8. DOI: 10.1016/j.ahj.2015.07.006

68. Pastori D, Farcomeni A, Poli D, Antonucci E, Angelico F, Del Ben M et al. Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score. Internal and Emergency Medicine. 2016;11(2):199–204. DOI: 10.1007/s11739-015-1326-1

69. Rivera-Caravaca JM, Marín F, Esteve-Pastor MA, Raña-Míguez P, Anguita M, Muñiz J et al. Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. The American Journal of Cardiology. 2017;120(12):2176–81. DOI: 10.1016/j.amjcard.2017.09.003

70. Andrade JG, Deyell MW, Wong GC, Macle L. Antithrombotic Therapy for Atrial Fibrillation and Coronary Disease Demystified. Canadian Journal of Cardiology. 2018;34(11):1426–36. DOI: 10.1016/j.cjca.2018.08.028

71. Fischer Q, Georges JL, Le Feuvre C, Sharma A, Hammoudi N, Berman E et al. Optimal long-term antithrombotic treatment of patients with stable coronary artery disease and atrial fibrillation: “OLTAT registry”. International Journal of Cardiology. 2018;264:64–9. DOI: 10.1016/j.ijcard.2018.03.018

72. Lamberts M, Gislason GH, Lip GYH, Lassen JF, Olesen JB, Mikkelsen AP et al. Antiplatelet Therapy for Stable Coronary Artery Disease in Atrial Fibrillation Patients Taking an Oral Anticoagulant: A Nationwide Cohort Study. Circulation. 2014;129(15):1577–85. DOI: 10.1161/CIRCULATIONAHA.113.004834

73. Lemesle G, Ducrocq G, Elbez Y, Van Belle E, Goto S, Cannon CP et al. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events: VKA and APT in patients with stable CAD and AF. Clinical Cardiology. 2017;40(10):932–9. DOI: 10.1002/clc.22750

74. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 2019;ehz425. [Epub ahead of print]. DOI: 10.1093/eurheartj/ehz425

75. Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M et al. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. New England Journal of Medicine. 2019;381(12):1103–13. DOI: 10.1056/NEJMoa1904143

76. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database of Systematic Reviews. 2007;3:CD006186. DOI: 10.1002/14651858.CD006186.pub2

77. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012;125(5):669–76. DOI: 10.1161/CIRCULATIONAHA.111.055970

78. Bahit MC, Lopes RD, Wojdyla DM, Hohnloser SH, Alexander JH, Lewis BS et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: Insights from the ARISTOTLE trial. International Journal of Cardiology. 2013;170(2):215–20. DOI: 10.1016/j.ijcard.2013.10.062

79. Mahaffey KW, Stevens SR, White HD, Nessel CC, Goodman SG, Piccini JP et al. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. European Heart Journal. 2014;35(4):233–41. DOI: 10.1093/eurheartj/eht428

80. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Archives of Internal Medicine. 2012;172(5):397– 402. DOI: 10.1001/archinternmed.2011.1666

81. Douxfils J, Buckinx F, Mullier F, Minet V, Rabenda V, Reginster J et al. Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of the American Heart Association. 2014;3(3):e000515. DOI: 10.1161/JAHA.113.000515

82. Chatterjee S, Sharma A, Uchino K, Biondi-Zoccai G, Lichstein E, Mukherjee D. Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials. Coronary Artery Disease. 2013;24(8):628–35. DOI: 10.1097/MCA.0000000000000031

83. Tornyos A, Vorobcsuk A, Kupó P, Aradi D, Kehl D, Komócsi A. Apixaban and risk of myocardial infarction: meta-analysis of randomized controlled trials. Journal of Thrombosis and Thrombolysis. 2015;40(1):1–11. DOI: 10.1007/s11239-014-1096-z

84. Mak K-H. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open. 2012;2(5):e001592. DOI: 10.1136/bmjopen-2012-001592

85. Loke YK, Pradhan S, Yeong JK, Kwok CS. Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison: Coronary risks with new oral anticoagulants. British Journal of Clinical Pharmacology. 2014;78(4):707– 17. DOI: 10.1111/bcp.12376

86. Tornyos A, Kehl D, D’Ascenzo F, Komócsi A. Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment. Progress in Cardiovascular Diseases. 2016;58(5):483–94. DOI: 10.1016/j.pcad.2015.12.001

87. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. The New England Journal of Medicine. 2016;375(25):2423–34. DOI: 10.1056/NEJMoa1611594

88. Mega JL, Braunwald E, Wiviott SD, Bassand J-P, Bhatt DL, Bode C et al. Rivaroxaban in patients with a recent acute coronary syndrome. The New England Journal of Medicine. 2012;366(1):9–19. DOI: 10.1056/NEJMoa1112277

89. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal. 2016;37(3):267–315. DOI: 10.1093/eurheartj/ehv320

90. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine. 2017;377(14):1319–30. DOI: 10.1056/NEJMoa1709118

91. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. European Heart Journal. 2011;32(22):2781–9. DOI: 10.1093/eurheartj/ehr113

92. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P et al. Apixaban with antiplatelet therapy after acute coronary syndrome. The New England Journal of Medicine. 2011;365(8):699–708. DOI: 10.1056/NEJMoa1105819

93. Lee CJ-Y, Gerds TA, Carlson N, Bonde AN, Gislason GH, Lamberts M et al. Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 2018;72(1):17–26. DOI: 10.1016/j.jacc.2018.04.036


Для цитирования:


Кобалава Ж.Д., Лазарев П.В. Риск развития коронарных осложнений при фибрилляции предсердий. Кардиология. 2020;60(1):43-52. https://doi.org/10.18087/cardio.2020.1.n828

For citation:


Kobalava Z.D., Lazarev P.V. Risk of Coronary Events in Atrial Fibrillation. Kardiologiia. 2020;60(1):43-52. (In Russ.) https://doi.org/10.18087/cardio.2020.1.n828

Просмотров: 326


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)